Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07426913 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 30, 2026 → Jul 30, 2027
See other at-risk trials from Virginia Commonwealth University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 30, 2026 to Jul 30, 2027
    • Study completion pushed from Feb 28, 2027 to Sep 28, 2027
    • Secondary endpoints: details revised at 4 of 4 entries
    • Eligibility criteria expanded, about 5 words
  2. Re-verified, no change to tracked fieldsv5
  3. Eligibility criteria expanded, about 8 words
    • Site contacts updated at 3 of 3 sites
    v4
  4. Recruitment opened
    • Start date: Jul 1, 2026 to May 20, 2026
    • Site details revised at 3 of 3 sites
    v3
  5. Start date: Mar 1, 2026 to Jul 1, 2026
    • Primary completion pushed from Jun 30, 2026 to Jul 30, 2026
    • Study completion pushed from Jun 30, 2026 to Feb 28, 2027
    • Site contacts updated at 3 of 3 sites
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).
Trial Details
NCT Number NCT07426913
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
Related terms Breast Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov